{"id":1513,"date":"2017-10-27T12:14:08","date_gmt":"2017-10-27T12:14:08","guid":{"rendered":"https:\/\/ilts.org\/?post_type=event&p=1513"},"modified":"2018-07-24T12:19:04","modified_gmt":"2018-07-24T12:19:04","slug":"nash-consensus-conference","status":"publish","type":"event","link":"https:\/\/old.ilts.org\/events\/nash-consensus-conference\/","title":{"rendered":"NAFLD\/NASH Consensus Conference"},"content":{"rendered":"

\"\"<\/strong><\/p>\n

<\/div><\/p><\/div>\n

<\/div><\/p><\/div>\n

ILTS Consensus Conference <\/strong><\/p>\n

NAFLD\/NASH: From medical treatment to liver transplantation <\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

Thursday, February 15th<\/sup>, 2018<\/strong> at: <\/strong><\/p>\n

San Servolo Residential and Study Centre<\/strong><\/p>\n

Isola di San Servolo n. 1 \u2013 30124 Venice, Italy
\n<\/strong><\/p>\n

Phone: +39 041 276 5001<\/strong><\/p>\n

Fax: +39 041 276 5402<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

<\/div><\/p><\/div>\n

<\/div><\/p><\/div>\n

The Conference will convene key opinion leaders and experts, primarily hepatologists, to focus on epidemiology and prevention of NASH, medical treatment of NASH (standard of care and new potential drugs),\u00a0management of end stage liver disease and cirrhosis complications, liver transplantation for NASH, immunosuppression management strategies and best practices in cases with NASH recurrence or de novo occurrence after transplant. The new scenario in hepatology due to the efficacy and safety of new anti-HCV therapy before and after liver transplantation will be also considered.<\/p>\n

<\/div><\/p><\/div>\n

2 introductory Lectures will consider fundamental questions:<\/p>\n

    \n
  • Why NASH? Because HCV is disappearing?<\/li>\n
  • Are we also eliminating HCV in special populations?<\/li>\n<\/ul>\n

    <\/div><\/p><\/div>\n

    6 lectures will go on to address:<\/p>\n

      \n
    • Epidemiology and prevention,<\/li>\n
    • Medical treatment: lifestyle changes and pharmacological therapy,<\/li>\n
    • Risk of hepatocellular carcinoma: surveillance and management,<\/li>\n
    • End stage liver disease and liver transplantation,<\/li>\n
    • Management of recurrent and de novo NAFLD\/NASH after liver transplantation,<\/li>\n
    • Pediatric population.<\/li>\n<\/ul>\n

      <\/div><\/p><\/div>\n

      Exchange ideas in a friendly, stimulating environment.<\/p>\n

      <\/div><\/p><\/div>\n

      <\/div><\/p><\/div>\n
      \n